As MD is increasingly recognized as a multi-faceted metabolic disease [43], improved modeling may also arise from combining circulating lipid-modulating approaches with other transgenic models that mimic MD abnormalities, such as telomerase RNA component (TERC) inactivation [44] or transforming growth factor-beta (TGF-β) overexpression [45]. This evidence concerns the gene TGFB1 and Other metabolic disease.